270 related articles for article (PubMed ID: 10357952)
41. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
Lin Y; Kahn JA; Hillensjö T
Hum Reprod; 1999 Apr; 14(4):885-8. PubMed ID: 10221213
[TBL] [Abstract][Full Text] [Related]
42. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
[TBL] [Abstract][Full Text] [Related]
43. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
44. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
45. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
[TBL] [Abstract][Full Text] [Related]
46. GnRH antagonist pre-treatment: one centre's experience for IVF-ICSI cycle scheduling.
Viardot-Foucault V; Nadarajah S; Lye WK; Tan HH
Reprod Biomed Online; 2015 Apr; 30(4):366-72. PubMed ID: 25684093
[TBL] [Abstract][Full Text] [Related]
47. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
Peñarrubia J; Balasch J; Fábregues F; Creus M; Casamitjana R; Ballescá JL; Puerto B; Vanrell JA
Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
[TBL] [Abstract][Full Text] [Related]
48. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
49. In vitro fertilisation. A review of drug therapy and clinical management.
Jennings JC; Moreland K; Peterson CM
Drugs; 1996 Sep; 52(3):313-43. PubMed ID: 8875126
[TBL] [Abstract][Full Text] [Related]
50. GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol.
Takahashi K; Mukaida T; Tomiyama T; Goto T; Oka C
J Assist Reprod Genet; 2004 Sep; 21(9):317-22. PubMed ID: 15587144
[TBL] [Abstract][Full Text] [Related]
51. Subpopulations of human granulosa-luteal cells obtained from gonadotropin- or gonadotropin-releasing hormone agonist/gonadotropin-treated follicles in in vitro fertilization-embryo transfer cycles.
Gersak K; Tomazevic T
J Assist Reprod Genet; 1999 Oct; 16(9):488-91. PubMed ID: 10530403
[TBL] [Abstract][Full Text] [Related]
52. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
[TBL] [Abstract][Full Text] [Related]
53. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles.
Hwang JL; Huang LW; Hsieh BC; Tsai YL; Huang SC; Chen CY; Hsieh ML; Chen PH; Lin YH
Hum Reprod; 2003 Jan; 18(1):45-9. PubMed ID: 12525439
[TBL] [Abstract][Full Text] [Related]
54. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
Valbuena D; Pellicer A; Guanes PP; Remohí J; Simón C
Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
[TBL] [Abstract][Full Text] [Related]
55. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix.
Tavaniotou A; Albano C; Van Steirteghem A; Devroey P
Reprod Biomed Online; 2003 Jun; 6(4):421-6. PubMed ID: 12831586
[TBL] [Abstract][Full Text] [Related]
56. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol.
Humaidan P; Bungum L; Bungum M; Hald F; Agerholm I; Blaabjerg J; Yding Andersen C; Lindenberg S
Reprod Biomed Online; 2005 Dec; 11(6):679-84. PubMed ID: 16417730
[TBL] [Abstract][Full Text] [Related]
57. Effect of Gonadotrophin-Releasing Hormone Agonist Addition for Luteal Support on Pregnancy Outcome in vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: A Meta-Analysis Based on Randomized Controlled Trials.
Ma X; Du W; Hu J; Yang Y; Zhang X
Gynecol Obstet Invest; 2020; 85(1):13-25. PubMed ID: 31422404
[TBL] [Abstract][Full Text] [Related]
58. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
[TBL] [Abstract][Full Text] [Related]
59. Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET).
Mettler L; Brandenburg K
Clin Exp Obstet Gynecol; 2000; 27(2):103-5. PubMed ID: 10968345
[TBL] [Abstract][Full Text] [Related]
60. Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study.
Strezsak V; Allignol A; Bühler K; Fischer R; Hubbard J; Longobardi S; Lispi M; Schertz J; Verpillat P
Gynecol Obstet Invest; 2023; 88(4):214-225. PubMed ID: 37369184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
